Potent VEGFR inhibitor (IC50
= 0.035 nM); also inhibits c-Met, KIT, RET, FLT4, AXL, FLT3, FLT1 and Tie2 (IC50
values are 1.3, 4.6, 5.2, 6, 7, 11.3, 12 and 14.3 nM, respectively). Induces intratumoral hypoxia and apoptosis. Reduces tumor invasion and metastasis in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.
You et al.
Cancer Res., 2012;71:4758
Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Yakes et al.
Mol.Cancer Ther., 2011;10:2298